Skip to main content

Magellan Health, FLIR Systems: 5 Top Stock Gainers for Monday

Magellan Health, FLIR Systems, Brookfield Property Partners, ViewRay and Pandion Therapeutics are five top stock gainers for Monday.

Stocks ended lower Monday, dragged down by an increase in coronavirus infections and fears of tougher restrictions and lockdowns.

Here are some of the big stock gainers in the market on Monday.

1. Magellan Health | Percentage Increase 13%

Magellan Health  (MGLN) - Get Magellan Health, Inc. Report was higher after the health-care management company agreed to be acquired by health-care insurer Centene  (CNC) - Get Centene Corporation Report for $95 a share. The enterprise value of the deal is $2.2 billion.

2. FLIR Systems | Percentage Increase 19%

Shares of FLIR Systems  (FLIR) - Get FLIR Systems, Inc. Report climbed following news that Teledyne (TDY) - Get Teledyne Technologies Incorporated Report would be buying the thermal image technology and hardware provider in a cash-and-stock deal valued at roughly $8 billion.

Scroll to Continue

TheStreet Recommends

3. Brookfield Property Partners | Percentage Increase 18%

Brookfield Property Partners  (BPY) - Get Brookfield Property Partners L.P. Report advanced after Brookfield Asset Management said it and some of its institutional partners proposed buying out other investors in the real estate company in a deal valuing the mall operator at $5.9 billion.

4. ViewRay | Percentage Increase 68%

ViewRay  (VRAY) - Get ViewRay Inc. Report soared after the medical-device maker projected results that exceeded Wall Street's expectations. The company said it expected fourth-quarter revenue to total $18 million, up from $17 million a year ago, and higher than the FactSet consensus estimate of $10.74 million. Full-year revenue is expected to total $57 million, down from $88 million a year, but ahead of Wall Street's call for $50 million.

5. Pandion Therapeutics | Percentage Increase 48%

Shares of Pandion Therapeutics PAND climbed after the biopharma reported top-line data from its Phase 1a single-dose, healthy-volunteer clinical trial for PT101. The drug is being developed to treat ulcerative colitis, systemic lupus erythematosus, and other autoimmune diseases.